ADVERTISEMENT
EBRT May Be Superior to CTURBT for Non–Muscle Invasive Bladder Cancer
Results from a meta-analysis suggest that en bloc transurethral resection of bladder tumor (EBRT) is superior toconventional transurethral resection of bladder tumor (CTURBT) as treatment for patients with non–muscle invasive bladder cancer (NMIBC; World J Surg Oncol. 2020 Jan 4. Epub ahead of print).
The purpose of the meta-analysis by Dong Zhang, MD, Department of Urology & Nephrology, Ningbo First Hospital, Hospital of Zhejiang University, China,and colleagues was to compare the safety and efficacy of EBRT with CTURBT.
A total of 19 studies comprising 2651 patients with NMIBC were included in the analysis through November 2019; of the patients included, 1369 underwent EBRT and 1282 had CTURBT.
End points being examined included operation, hospitalization, and catherization times; complications; ratio of bladder detrusor muscle; residual tumor on the base; ratio of same site recurrence; as well as 12-, 24-, and 36-month recurrence rates.
Patients who underwent EBRT had significantly lower hospitalization and catheterization times, postoperative complications, and 24-month recurrence rates than those who underwent CTURBT.
There were no significant differences found in operation time, ratio of bladder detrusor muscle, residual tumor on the base, ratio of same site recurrence, and 12-month and 36-month recurrence rates.
Pooled data suggest that EBRT is a superior treatment method for NMIBC.
“Based on the included 19 articles, EBRT had a significantly lower AT, HT, intraoperative and postoperative complications, and 24-month recurrence rate than those treated with CTURBT,” Dr Zhang and colleagues concluded.
To overcome study limitations and confirm these outcomes, well-designed randomized controlled trials are needed, they added.—Kaitlyn Manasterski
